• SPX
  • $5,969.34
  • 0.35 %
  • $20.63
  • DJI
  • $44,296.51
  • 0.97 %
  • $426.16
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,003.65
  • 0.16 %
  • $31.23
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News & Analysis

BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$7.62

$0.13

(1.74%)

Day's range
$7.42
Day's range
$7.66
50-day range
$6.85
Day's range
$8.44
  • Country: US
  • ISIN: US09058V1035
52 wk range
$4.03
Day's range
$8.88


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.68
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (BCRX)
  • Company BioCryst Pharmaceuticals, Inc.
  • Price $7.62
  • Changes Percentage (1.74%)
  • Change $0.13
  • Day Low $7.42
  • Day High $7.66
  • Year High $8.88

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/19/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $16.00
  • High Stock Price Target $25.00
  • Low Stock Price Target $7.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.07
  • Trailing P/E Ratio -5.9
  • Forward P/E Ratio -5.9
  • P/E Growth -5.9
  • Net Income $-226,539,000

Income Statement

Quarterly

Annual

Latest News of BCRX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

BioCryst Pharmaceuticals, Inc. Frequently Asked Questions

  • What is the BioCryst Pharmaceuticals, Inc. stock price today?

    Today's price of BioCryst Pharmaceuticals, Inc. is $7.62 — it has increased by +1.74% in the past 24 hours. Watch BioCryst Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does BioCryst Pharmaceuticals, Inc. release reports?

    Yes, you can track BioCryst Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the BioCryst Pharmaceuticals, Inc. stock forecast?

    Watch the BioCryst Pharmaceuticals, Inc. chart and read a more detailed BioCryst Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is BioCryst Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by BioCryst Pharmaceuticals, Inc. stock ticker.

  • How to buy BioCryst Pharmaceuticals, Inc. stocks?

    Like other stocks, BCRX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is BioCryst Pharmaceuticals, Inc.'s EBITDA?

    BioCryst Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in BioCryst Pharmaceuticals, Inc.’s financial statements.

  • What is the BioCryst Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.6835570227, which equates to approximately -68.36%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in BioCryst Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including BioCryst Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. BioCryst Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for BioCryst Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review BioCryst Pharmaceuticals, Inc.’s technical analysis.

  • A revenue figure for BioCryst Pharmaceuticals, Inc. for its last quarter?

    BioCryst Pharmaceuticals, Inc. published it's last quarterly revenues at $117.09 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.